2022 Annual Meeting | Aducanumab: A Conversation with David Knopman About the Approval Process and the Future of Dementia Care

Date Tuesday 04/05/22

Time 04:00 PM - 04:45 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Hubs (HeadTalks)

Director(s) Joyce K. Lee-Iannotti, MD, FAAN, David Y. Hwang, MD, FAAN, David S. Knopman, MD, FAAN

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives Come learn more about the controversial use of Aducanumab as a treatment for Alzheimer’s disease from a leading authority in Cognitive and Behavioral Neurology, Dr. David Knopman. Dr. Knopman will guide us in the development of aducanumab, the analysis of the clinical trial data, the approval by the FDA and the subsequent decision by CMS to limit coverage to persons in a controlled clinical trial. He will also update us on forthcoming treatments and the future of dementia care.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
04:00 PM - 04:45 PM PDT	Discussion	Aducanumab: A Conversation with David Knopman About the Approval Process and the Future of Dementia Care Joyce K. Lee-Iannotti, MD, FAAN, David S. Knopman, MD, FAAN, David Y. Hwang, MD, FAAN

Faculty Disclosures
Joyce K. Lee-Iannotti, MD, FAAN	Dr. Lee-Iannotti has nothing to disclose.
David Y. Hwang, MD, FAAN	Dr. Hwang has received publishing royalties from a publication relating to health care. Dr. Hwang has a non-compensated relationship as a Board of Directors with Neurocritical Care Society that is relevant to AAN interests or activities.
David S. Knopman, MD, FAAN	Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.